Alzamend Neuro, INC. (ALZN) — SEC Filings

Overview

Alzamend Neuro, INC. (ALZN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Dec 9, 2025: Alzamend Neuro, Inc. (ALZN) reported a net loss of $1.0 million for the three months ended October 31, 2025, a decrease from $1.4 million in the same period of 2024. For the six months ended October 31, 2025, the net loss was $3.7 million, an increase from $2.3 million in the prior year. Research an

Sentiment Summary

Across 48 filings, the sentiment breakdown is: 5 bearish, 43 neutral. The dominant filing sentiment for Alzamend Neuro, INC. is neutral.

Filing Type Overview

Alzamend Neuro, INC. (ALZN) has filed 6 10-Q, 29 8-K, 2 10-K, 3 S-1/A, 3 DEFA14A, 2 DEF 14A, 1 S-1, 1 8-K/A, 1 SC 13D/A with the SEC between Jan 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (48)

• Alzamend Neuro's Losses Mount Amid R&D Surge, Going Concern Doubts — 10-Q · Dec 9, 2025 Risk: high
  Alzamend Neuro, Inc. (ALZN) reported a net loss of $1.0 million for the three months ended October 31, 2025, a decrease from $1.4 million in the same period of
• Alzamend Neuro Files 8-K — 8-K · Nov 18, 2025 Risk: low
  Alzamend Neuro, Inc. filed an 8-K on November 18, 2025, reporting other events and financial statements. The company, incorporated in Delaware, is in the pharma
• Alzamend Neuro Files 8-K with Corporate Updates — 8-K · Oct 14, 2025 Risk: low
  Alzamend Neuro, Inc. filed an 8-K on October 14, 2025, reporting amendments to its Articles of Incorporation or Bylaws and filing financial statements and exhib
• Alzamend Neuro Files 8-K on Equity Sales — 8-K · Oct 9, 2025 Risk: medium
  Alzamend Neuro, Inc. filed an 8-K on October 9, 2025, reporting unregistered sales of equity securities. The filing also includes financial statements and exhib
• Alzamend Neuro Files 8-K on Equity Sales — 8-K · Sep 25, 2025 Risk: medium
  Alzamend Neuro, Inc. filed an 8-K on September 25, 2025, reporting unregistered sales of equity securities and financial statements. The company, incorporated i
• Alzamend Neuro's R&D Soars, Net Loss Triples Amid Reverse Splits — 10-Q · Sep 10, 2025 Risk: high
  Alzamend Neuro, Inc. (ALZN) reported a significant increase in net loss for the three months ended July 31, 2025, reaching $2,702,684, a substantial rise from $
• Alzamend Neuro Files 8-K on Equity Sales — 8-K · Aug 1, 2025 Risk: medium
  Alzamend Neuro, Inc. filed an 8-K on August 1, 2025, reporting unregistered sales of equity securities. The filing also includes financial statements and exhibi
• Alzamend Neuro Files 8-K on Operations — 8-K · Jul 23, 2025 Risk: low
  Alzamend Neuro, Inc. filed an 8-K on July 23, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and
• Alzamend Neuro Continues R&D Focus, Zero Revenue in FY25 — 10-K · Jul 22, 2025 Risk: high
  Alzamend Neuro, Inc. reported no revenue for the fiscal year ended April 30, 2025, consistent with its pre-commercial stage as a pharmaceutical company. The net
• Alzamend Neuro Files 8-K with Corporate Updates — 8-K · Jul 9, 2025 Risk: low
  Alzamend Neuro, Inc. filed an 8-K on July 9, 2025, reporting amendments to its articles of incorporation or bylaws and financial statements. The company, incorp
• Alzamend Neuro Files 8-K with Corporate Updates — 8-K · May 8, 2025 Risk: low
  Alzamend Neuro, Inc. filed an 8-K on May 8, 2025, reporting amendments to its articles of incorporation or bylaws, a Regulation FD disclosure, and financial sta
• Alzamend Neuro Files 8-K on Shareholder Votes and Financials — 8-K · Apr 25, 2025 Risk: low
  Alzamend Neuro, Inc. filed an 8-K on April 25, 2025, reporting on matters submitted to a vote of security holders and financial statements. The company, incorpo
• Alzamend Neuro Files S-1/A Amendment — S-1/A · Mar 27, 2025 Risk: medium
  Alzamend Neuro, Inc. filed an S-1/A amendment on March 27, 2025, for its registration statement. The company, incorporated in Delaware, is in the pharmaceutical
• Alzamend Neuro Files Proxy Statement Amendment — DEFA14A · Mar 19, 2025 Risk: low
  Alzamend Neuro, Inc. filed an amended proxy statement (DEFA14A) on March 19, 2025. This filing is an amendment to a previous filing and is considered definitive
• Alzamend Neuro Files Proxy Statement Amendment — DEFA14A · Mar 17, 2025 Risk: low
  Alzamend Neuro, Inc. filed an amendment (Amendment No. 1) to its Definitive Proxy Statement on March 17, 2025. This filing concerns the solicitation of proxies
• Alzamend Neuro Proxy Statement Filed for April 25 Meeting — DEF 14A · Mar 13, 2025 Risk: medium
  Alzamend Neuro, Inc. filed its definitive proxy statement on March 13, 2025, for its annual meeting on April 25, 2025. The company, focused on treatments for Al
• Alzamend Neuro Files 10-Q, Details Financials — 10-Q · Mar 10, 2025 Risk: medium
  Alzamend Neuro, Inc. filed a 10-Q for the period ending January 31, 2025. The company's fiscal year ends on April 30th. The filing details financial information
• Alzamend Neuro Files 8-K for Bylaws, Exhibits — 8-K · Mar 3, 2025 Risk: low
  Alzamend Neuro, Inc. filed an 8-K on March 3, 2025, reporting amendments to its Articles of Incorporation or Bylaws and submitting financial statements and exhi
• Alzamend Neuro Files 8-K on Agreements and Equity Sales — 8-K · Feb 28, 2025 Risk: medium
  Alzamend Neuro, Inc. filed an 8-K on February 28, 2025, reporting on the entry into a material definitive agreement, unregistered sales of equity securities, an
• Alzamend Neuro Files 8-K on Financials — 8-K · Dec 12, 2024 Risk: medium
  Alzamend Neuro, Inc. filed an 8-K on December 12, 2024, reporting on its results of operations and financial condition. The filing details financial statements
• Alzamend Neuro Files 10-Q for Q2 2024 — 10-Q · Dec 11, 2024 Risk: medium
  Alzamend Neuro, Inc. filed its 10-Q for the period ending October 31, 2024. The company reported financial results and provided updates on its business operatio
• Alzamend Neuro Files 8-K with Financial Updates — 8-K · Oct 15, 2024 Risk: low
  Alzamend Neuro, Inc. filed an 8-K on October 15, 2024, reporting on financial statements and exhibits. The company, incorporated in Delaware, is involved in pha
• Alzamend Neuro Enters Material Definitive Agreement — 8-K · Oct 3, 2024 Risk: medium
  Alzamend Neuro, Inc. announced on October 3, 2024, that it has entered into a Material Definitive Agreement. The company also filed financial statements and exh
• Alzamend Neuro Files 10-Q for Period Ending July 31, 2024 — 10-Q · Sep 11, 2024 Risk: medium
  Alzamend Neuro, Inc. filed a 10-Q for the period ending July 31, 2024. The company reported its financial results and provided updates on its business operation
• Alzamend Neuro Files 8-K — 8-K · Jul 31, 2024 Risk: low
  Alzamend Neuro, Inc. filed an 8-K on July 31, 2024, reporting on financial statements and exhibits, and a Regulation FD Disclosure. The company, incorporated in
• Alzamend Neuro Files 2024 10-K — 10-K · Jul 30, 2024 Risk: medium
  Alzamend Neuro, Inc. filed its 10-K for the fiscal year ending April 30, 2024, reporting on its operations and financial condition. The company is focused on th
• Alzamend Neuro Files 8-K with Corporate Updates — 8-K · Jul 12, 2024 Risk: low
  Alzamend Neuro, Inc. filed an 8-K on July 12, 2024, reporting amendments to its articles of incorporation or bylaws, a Regulation FD disclosure, and financial s
• Alzamend Neuro Files 8-K on Shareholder Votes and Financials — 8-K · Jul 8, 2024 Risk: low
  Alzamend Neuro, Inc. filed an 8-K on July 8, 2024, reporting on matters submitted to a vote of security holders and including financial statements and exhibits.
• Alzamend Neuro Files S-1/A Amendment — S-1/A · Jul 3, 2024 Risk: medium
  Alzamend Neuro, Inc. filed an S-1/A amendment on July 3, 2024, to its registration statement. The company, incorporated in Delaware, is in the pharmaceutical pr
• Alzamend Neuro Files S-1/A Amendment — S-1/A · Jun 26, 2024 Risk: medium
  Alzamend Neuro, Inc. filed an amendment (S-1/A) on June 26, 2024, to its registration statement. The company, incorporated in Delaware, is in the pharmaceutical
• Alzamend Neuro Files Proxy Statement Amendment — DEFA14A · Jun 11, 2024 Risk: low
  Alzamend Neuro, Inc. filed an amendment (DEFA14A) on June 11, 2024, regarding its proxy statement. The filing indicates no fee was required for this submission,
• Alzamend Neuro Files S-1 for Potential Stock Offering — S-1 · Jun 3, 2024 Risk: medium
  Alzamend Neuro, Inc. filed an S-1 registration statement on June 3, 2024, to register an unspecified number of securities. The company, headquartered in Atlanta
• Alzamend Neuro Files Proxy Statement for Annual Meeting — DEF 14A · May 31, 2024 Risk: medium
  Alzamend Neuro, Inc. filed a DEF 14A proxy statement on May 31, 2024, for its annual meeting on July 8, 2024. The filing details executive compensation, board n
• Alzamend Neuro Files 8-K — 8-K · May 22, 2024 Risk: low
  Alzamend Neuro, Inc. filed an 8-K on May 22, 2024, reporting on Regulation FD disclosures and financial statements. The company, incorporated in Delaware, has i
• Alzamend Neuro Files 8-K — 8-K · May 15, 2024 Risk: low
  Alzamend Neuro, Inc. filed an 8-K on May 15, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain sp
• Alzamend Neuro Files 8-K for Financial Statements — 8-K · May 13, 2024 Risk: low
  Alzamend Neuro, Inc. filed an 8-K on May 13, 2024, to report financial statements and exhibits. The filing does not contain specific financial figures or detail
• Alzamend Neuro Files 8-K/A Amendment — 8-K/A · May 10, 2024 Risk: medium
  Alzamend Neuro, Inc. filed an amendment (Amendment No. 1) to its Form 8-K on May 10, 2024, to include a legal opinion from Olshan Frome Wolosky LLP regarding th
• Alzamend Neuro Changes Independent Accountants — 8-K · May 9, 2024 Risk: medium
  Alzamend Neuro, Inc. filed an 8-K on May 9, 2024, to report a change in its certifying accountant. The company has dismissed its previous independent registered
• Alzamend Neuro Terminates Material Agreement — 8-K · May 7, 2024 Risk: medium
  Alzamend Neuro, Inc. announced on May 7, 2024, the termination of a material definitive agreement. The company also disclosed information related to Regulation
• Alzamend Neuro Files 8-K on Voting Matters and Financials — 8-K · May 1, 2024 Risk: low
  Alzamend Neuro, Inc. filed an 8-K on May 1, 2024, reporting on matters submitted to a vote of security holders and financial statements. The filing details the
• Alzamend Neuro Files 8-K: Material Agreement & Equity Sales — 8-K · Apr 30, 2024 Risk: medium
  Alzamend Neuro, Inc. announced on April 30, 2024, that it entered into a material definitive agreement. The company also reported the creation of a direct finan
• Alzamend Neuro Faces Delisting, Reports Equity Sales — 8-K · Mar 29, 2024 Risk: high
  Alzamend Neuro, Inc. filed an 8-K on March 29, 2024, reporting an entry into a material definitive agreement and a notice of delisting or failure to satisfy con
• Alzamend Neuro, Inc. Files 10-Q for Period Ending January 31, 2024 — 10-Q · Mar 25, 2024 Risk: medium
  Alzamend Neuro, Inc. (ALZN) filed a Quarterly Report (10-Q) with the SEC on March 25, 2024. Alzamend Neuro, Inc. filed a 10-Q report for the period ending Janua
• Alzamend Neuro Files 8-K for Material Agreements — 8-K · Mar 22, 2024 Risk: medium
  Alzamend Neuro, Inc. announced on March 22, 2024, that it entered into a Material Definitive Agreement. The company also made material modifications to the righ
• Alzamend Neuro Files 8-K with Bylaw Amendments — 8-K · Mar 7, 2024 Risk: low
  Alzamend Neuro, Inc. filed an 8-K on March 7, 2024, reporting amendments to its Articles of Incorporation or Bylaws and including financial statements and exhib
• Alzamend Neuro Faces Delisting, Sells Unregistered Equity — 8-K · Feb 2, 2024
  Alzamend Neuro, Inc. filed an 8-K on February 2, 2024, reporting a material definitive agreement, unregistered sales of equity securities, and amendments to its
• Ault Group Files 4th Amendment on Alzamend Neuro Stake — SC 13D/A · Jan 25, 2024
  Milton C. Ault III and his affiliated entities, including Ault Alliance, Inc., filed Amendment No. 4 to their Schedule 13D on January 25, 2024, regarding their
• Alzamend Neuro 8-K: Executive Compensation Arrangements Updated — 8-K · Jan 5, 2024
  Alzamend Neuro, Inc. filed an 8-K on January 5, 2024, reporting changes in its executive compensation arrangements. This filing indicates potential adjustments

Risk Profile

Risk Assessment: Of ALZN's 45 recent filings, 4 were flagged as high-risk, 22 as medium-risk, and 19 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Alzamend Neuro, INC.'s most recent 10-Q filing (Dec 9, 2025):

• Revenue: N/A
• Net Income: -$3.7 million
• EPS: -$1.33
• Debt-to-Equity: 0.16
• Cash Position: $4.4 million
• Operating Margin: N/A
• Total Assets: $5.1 million
• Total Debt: $0.7 million

Key Executives

• Stephan Jackman
• Henry Nisser
• Kenneth A. Schlesinger

Industry Context

Alzamend operates in the highly competitive and capital-intensive biotechnology sector, specifically focusing on treatments for neurological disorders like Alzheimer's. This field is characterized by long development cycles, high failure rates in clinical trials, and significant regulatory hurdles. Success hinges on groundbreaking research, substantial funding, and navigating complex approval processes.

Top Tags

financials (13) · filing (9) · corporate-governance (9) · sec-filing (7) · amendment (7) · equity-sale (6) · disclosure (5) · proxy-statement (5) · pharmaceutical (4) · 10-Q (4)

Key Numbers

• Net Loss (3 months): $1.0 million — Net loss for the three months ended October 31, 2025, decreased from $1.4 million in 2024.
• Net Loss (6 months): $3.7 million — Net loss for the six months ended October 31, 2025, increased from $2.3 million in 2024.
• Research and Development Expenses (6 months): $1.9 million — R&D expenses for the six months ended October 31, 2025, significantly increased from $517,659 in 2024.
• Cash Balance: $4.4 million — Cash as of October 31, 2025, up from $3.9 million at April 30, 2025.
• Accumulated Deficit: $62.2 million — Accumulated deficit as of October 31, 2025, indicating significant historical losses.
• Cash Used in Operating Activities (6 months): $3.5 million — Cash burn from operations for the six months ended October 31, 2025.
• Net Proceeds from Preferred Stock: $4.0 million — Cash provided by financing activities for the six months ended October 31, 2025.
• Common Shares Outstanding: 3,801,604 — Shares outstanding as of December 9, 2025, after two reverse stock splits.
• SEC File Number: 001-40483 — Identifier for Alzamend Neuro, Inc.
• EIN: 811822909 — Employer Identification Number
• Net Loss: $2.7M — Increased from $0.97M in Q3 2024, reflecting higher R&D.
• Research and Development Expenses: $1.74M — Significantly up from $0.21M in Q3 2024, indicating increased pipeline investment.
• Cash at End of Period: $5.62M — Increased from $3.95M at April 30, 2025, primarily from preferred stock issuance.
• Net Proceeds from Preferred Stock Issuance: $4.04M — Key financing activity for the three months ended July 31, 2025.
• Second Reverse Stock Split Ratio: 1-for-9 — Effective May 12, 2025, impacting share structure.

Related Companies

ALZM

Frequently Asked Questions